| Raymond L Comenzo, MD | |
|
800 Washington St, Boston, MA 02111-1552 | |
| (617) 636-5000 | |
| Not Available |
| Full Name | Raymond L Comenzo |
|---|---|
| Gender | Male |
| Speciality | Hematology |
| Experience | 38 Years |
| Location | 800 Washington St, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750352787 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 212755 (New York) | Primary |
| 207RH0000X | Internal Medicine - Hematology | 59940 (Massachusetts) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tufts Medical Center | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pratt Medical Group Inc | 3375515661 | 265 |
News Archive
Although it's widely accepted that inflammation is a critical underlying factor in a range of diseases, including the progression of cancer, little is known about its role when normal cells become tumor cells. Now, scientists from the Florida campus of The Scripps Research Institute have shed new light on exactly how the activation of a pair of inflammatory signaling pathways leads to the transformation of normal breast cells to cancer cells.
The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.
Scientists from the RIKEN Center for Integrative Medical Science (IMS) and Keio University School of Medicine in Japan have used single-cell RNA analysis to find that supercentenarians-meaning people over the age of 110-have an excess of a type of immune cell called cytotoxic CD4 T-cells.
Most EU member states have publicly funded healthcare systems and the proportion of pharmaceutical expenditure, as a portion of GDP remains high, particularly in countries such as Italy, Portugal, France, Spain and Greece.
› Verified 6 days ago
| Entity Name | Pratt Pathology Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659312189 PECOS PAC ID: 0345131637 Enrollment ID: O20040324000973 |
News Archive
Although it's widely accepted that inflammation is a critical underlying factor in a range of diseases, including the progression of cancer, little is known about its role when normal cells become tumor cells. Now, scientists from the Florida campus of The Scripps Research Institute have shed new light on exactly how the activation of a pair of inflammatory signaling pathways leads to the transformation of normal breast cells to cancer cells.
The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.
Scientists from the RIKEN Center for Integrative Medical Science (IMS) and Keio University School of Medicine in Japan have used single-cell RNA analysis to find that supercentenarians-meaning people over the age of 110-have an excess of a type of immune cell called cytotoxic CD4 T-cells.
Most EU member states have publicly funded healthcare systems and the proportion of pharmaceutical expenditure, as a portion of GDP remains high, particularly in countries such as Italy, Portugal, France, Spain and Greece.
› Verified 6 days ago
| Entity Name | Pratt Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275570319 PECOS PAC ID: 3375515661 Enrollment ID: O20040807000255 |
News Archive
Although it's widely accepted that inflammation is a critical underlying factor in a range of diseases, including the progression of cancer, little is known about its role when normal cells become tumor cells. Now, scientists from the Florida campus of The Scripps Research Institute have shed new light on exactly how the activation of a pair of inflammatory signaling pathways leads to the transformation of normal breast cells to cancer cells.
The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.
Scientists from the RIKEN Center for Integrative Medical Science (IMS) and Keio University School of Medicine in Japan have used single-cell RNA analysis to find that supercentenarians-meaning people over the age of 110-have an excess of a type of immune cell called cytotoxic CD4 T-cells.
Most EU member states have publicly funded healthcare systems and the proportion of pharmaceutical expenditure, as a portion of GDP remains high, particularly in countries such as Italy, Portugal, France, Spain and Greece.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Raymond L Comenzo, MD 800 Washington St, Boston, MA 02111-1552 Ph: () - | Raymond L Comenzo, MD 800 Washington St, Boston, MA 02111-1552 Ph: (617) 636-5000 |
News Archive
Although it's widely accepted that inflammation is a critical underlying factor in a range of diseases, including the progression of cancer, little is known about its role when normal cells become tumor cells. Now, scientists from the Florida campus of The Scripps Research Institute have shed new light on exactly how the activation of a pair of inflammatory signaling pathways leads to the transformation of normal breast cells to cancer cells.
The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.
Scientists from the RIKEN Center for Integrative Medical Science (IMS) and Keio University School of Medicine in Japan have used single-cell RNA analysis to find that supercentenarians-meaning people over the age of 110-have an excess of a type of immune cell called cytotoxic CD4 T-cells.
Most EU member states have publicly funded healthcare systems and the proportion of pharmaceutical expenditure, as a portion of GDP remains high, particularly in countries such as Italy, Portugal, France, Spain and Greece.
› Verified 6 days ago
Kaitlyn My-tu Lam, MBBS Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-724-7738 | |
Kui Toh Gerard Leong, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 Phone: 617-726-8862 | |
Ruma Rajbhandari, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-525-6841 | |
Alaka Ray, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2066 | |
Meghan E Sise, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2862 | |
Aaron Dickstein, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Box 233, Boston, MA 02111 Phone: 617-636-5883 Fax: 617-636-9292 | |
Dr. Felicia Elizabeth Patch, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 801 Massachusetts Ave, Crosstown 2, Boston, MA 02118 Phone: 617-414-4376 Fax: 617-414-4676 |